Tandem Diabetes Care To Integrate Automated Insulin Delivery System With Abbott's Freestyle Libre 2 Plus Sensor
Portfolio Pulse from Benzinga Newsdesk
Tandem Diabetes Care has announced the integration of its t:slim X2 insulin pump with Abbott's FreeStyle Libre 2 Plus sensor, marking the first time this 15-day CGM sensor is available for t:slim X2 users in the U.S. This collaboration enhances Tandem's Control-IQ hybrid closed-loop technology by providing users with a more advanced and longer-lasting CGM option.
January 08, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott's FreeStyle Libre 2 Plus sensor is now integrated with Tandem's t:slim X2 insulin pump, potentially increasing the sensor's market reach and usage in the U.S.
The integration with Tandem's insulin pump could lead to increased demand for Abbott's FreeStyle Libre 2 Plus sensor, as it becomes a part of a more comprehensive diabetes management system. This could positively impact Abbott's stock in the short term due to the potential for increased sales and market penetration.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Tandem Diabetes Care's t:slim X2 insulin pump now offers integration with Abbott's FreeStyle Libre 2 Plus sensor, potentially enhancing the product's appeal and competitive edge in the market.
The integration with Abbott's advanced CGM sensor could improve the attractiveness of Tandem's t:slim X2 insulin pump to potential customers, possibly leading to increased sales. This collaboration is likely to be viewed positively by investors, potentially leading to a short-term uptick in Tandem's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90